GLP-1 and IBMX induce IGF-1R expression through activation of the cAMP/PKA pathway. A, MIN6 cells were exposed for 18 h to GLP-1 (100 nm) to induce IGF-1R expression. This induction was blocked in the presence of the protein kinase A inhibitor H-89 (10 μm) or the cAMP antagonist Rp-CPT-cAMP (100 μm). Activation of Epac2 by 8-CPT-2′-O-Me-cAMP (50 μm) did not induce IGF-1R expression in the absence of GLP-1. B, induction of the IGF-1R by GLP-1 in MIN6 cells expression, which was not suppressed by the MAP kinase inhibitor PD98059 (PD, 50 μm), the PI 3-kinase inhibitors LY294002 (LY, 50 μm), or wortmannin (50 nm) nor by the Ca2+-channel blocker nimodipine (Nimo, 1 μm). C, induction of IGF-1R by IBMX (10 μm) was mimicked by exposing the cells to forskolin (FSK, 10 μm), or the protein kinase A activator SP-CPT-cAMP (100 μm). However, induction of IGF-1R expression was not increased by Epac2 activator 8-CPT-2′-O-Me-cAMP (50 μm) in the absence of IBMX. D, induction of IGF-1R expression by IBMX was not suppressed by PD98059, by LY294002, wortmannin (50 nm), nor by nimodipine. The levels are expressed as arbitrary units (a.u.). The data are the means ± S.D. from three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, not significant.